The patent was issued to Eurand, the developer of Amrix, and expires on February 26, 2025. In 2007, Cephalon acquired an exclusive license from Eurand to market Amrix in North America. The issued claims cover Eurand’s proprietary Diffucaps technology used to formulate Amrix as an extended-release capsule containing the muscle relaxant cyclobenzaprine.
The Amrix formulation allows, for the first time, a full day of cyclobenzaprine in a single dose medication for the treatment of acute painful musculoskeletal conditions.
Frank Baldino, Jr, chairman and CEO of Cephalon, said: “The issuance of this patent supports our investment in Amrix and its innovative technology, which offers the only once-daily treatment option for patients suffering from acute muscle spasms.”